sicklecellspeaks Archives - Good News! https://goodnewsplanet.com/tag/sicklecellspeaks/ Life Affirming Good News Fri, 26 Jun 2020 23:09:23 +0000 en-US hourly 1 https://goodnewsplanet.com/wp-content/uploads/2022/04/cropped-Earth-1200-×-1200-px-32x32.png sicklecellspeaks Archives - Good News! https://goodnewsplanet.com/tag/sicklecellspeaks/ 32 32 Ted W. Love, M.D. Sickle Cell, Global Blood Therapeutics https://goodnewsplanet.com/ted-w-love-m-d-sickle-cell-global-blood-therapeutics/ Wed, 19 Feb 2020 17:57:37 +0000 http://goodnewsplanet.com/?p=63658 Black History Month is when we Focus on Trailblazers in the African American Community. That includes medical pioneers who’ve made an impact on conditions like sickle cell disease… Agenetic Blood Disorder that Disproportionately Affects the Black Community. Although the Disease was discovered 100 years ago, it has historically lacked treatment options. Change has come. Dr. …

The post Ted W. Love, M.D. Sickle Cell, Global Blood Therapeutics appeared first on Good News!.

]]>

Black History Month is when we Focus on Trailblazers in the African American Community.
That includes medical pioneers who’ve made an impact on conditions like sickle cell disease… Agenetic Blood Disorder that Disproportionately Affects the Black Community. Although the Disease was discovered 100 years ago, it has historically lacked treatment options.
Change has come. Dr. Ted Love discusses the latest advances in managing this devastating disease, he is also the president and CEO of Global Blood Therapeutics, a Biotech Company based in San Francisco.
www.sicklecellspeaks.com
www.Oxbryta.com
Ted W. Love, M.D.
President and Chief Executive Officer, GBT
Dr. Love joined GBT in June 2014 as president and chief executive officer with broad leadership and management experience in the biotech/pharmaceutical industry. Before that, he was executive vice president, research and development and technical operations at Onyx Pharmaceuticals, Inc., where he played an instrumental role in initiating and completing several of Onyx’s first Phase 3 clinical trials. Prior to Onyx, Dr. Love served as president, chief executive officer and chairman of Nuvelo, Inc., where he led growth of the company to a market capitalization of $1 billion. Prior to that, he served as senior vice president, development at Theravance, Inc. Earlier in his career, Dr. Love held a number of senior management positions in medical affairs and product development at Genentech, where he served as chairman of Genentech’s Product Development Committee. As vice president, product development, Dr. Love oversaw the development strategy and execution leading to approvals of Rituxan®, Herceptin®, Xolair®, TNKase®, Raptiva and Avastin®. Dr. Love has served as a consultant in medicine in the Department of Cardiology at the Massachusetts General Hospital. He currently serves on the board of directors of Amicus Therapeutics, Inc., Portola Pharmaceuticals, Inc. and the Biotechnology Innovation Organization (BIO). Dr. Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital. Originally from Huntsville, AL, Dr. Love resides in San Francisco, CA.
https://www.cdc.gov/ncbddd/sicklecell/data.html
#ted #love #sickle #cell #disease #president #global #blood #therapeutic #therapeutics #black #history #month #trailblazers #african #american #community #agenetic #disorder #treatment #san #francisco #oxbryta #speaks #sicklecellspeaks

Share

The post Ted W. Love, M.D. Sickle Cell, Global Blood Therapeutics appeared first on Good News!.

]]> 63658